Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PUERTA: A P2A Multi-center, Randomized, Double-blind, Placebo-controlled Study Assessing Safety and Efficacy of the eNAMPT Targeting mAb ALT-100 in Moderate/Severe ARDS/VILI Patients

NCT05938036 is registered in ClinicalTrials.gov with Aqualung Therapeutics Corp. as lead sponsor.

NCT NCT05938036
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05938036 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PUERTA: A P2A Multi-center, Randomized, Double-blind, Placebo-controlled Study Assessing Safety and Efficacy of the eNAMPT Targeting mAb ALT-100 in Moderate/Severe ARDS/VILI Patients
Lead sponsor
Aqualung Therapeutics Corp.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 1, 2023
Completion date
July 1, 2027
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute respiratory distress syndrome (ards)